[{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"Antengene \/ Karyopharm Therapeutic","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Karyopharm Therapeutic"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Eltanexor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Eltanexor (KPT-8602/ATG-016) is an investigational novel SINE compound that functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus.

                          Brand Name : ATG-016

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 20, 2022

                          Lead Product(s) : Eltanexor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Orphan drug designation received from FDA for ATG-016 (eltanexor), selective inhibitor of nuclear export compound on the basis of positive data from Phase 1 study which demonstrated 53% ORR and median overall survival of 9.9 months for the treatment of ...

                          Brand Name : ATG-016

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2022

                          Lead Product(s) : Eltanexor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The National Medical Products Administration has approved the clinical trial of ATG-016 (eltanexor) in patients with intermediate and higher risk myelodysplastic syndrome according to the Revised IPSS-R after the failure of hypomethylating agents based t...

                          Brand Name : ATG-016

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 26, 2020

                          Lead Product(s) : Eltanexor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Karyopharm Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank